Women in Healthcare: Dr Mira Doig
Dr Mira Doig, ACM Bioanalytical Services, Technical Director
This month we celebrate women from various factions of healthcare who are all striving to achieve better outcomes for patients in their vastly different roles, showcasing their careers, interests, achievements and thoughts on the future. Turn to page 17 to meet some of the brightest stars across pharma, communications and healthcare.
With patient outcomes also clearly centre stage, on page 30 Craig Adkins says now is the time to level up care for patients with irritable bowel disorder (IBD), a condition for which there is an urgent need for a national disease strategy and the application of a standard of care across the country, while on page 34, looking at 15 years of biosimilars in Europe, Rebecca Guntern highlights that the opportunity to leverage biosimilars ‘as an obvious and sustainable way to increase patient access to medicines has never been closer’.
Elsewhere, on p28 there’s an interesting analysis by CRA on whether disease rarity is valued in cost-effectiveness analyses by decision makers in England, and on page 36 Mike Ward details the drugs hitting the market in 2021 that are likely to hit blockbuster status within five years.
And finally, some news on our competitions - the 2021 PharmaTimes Marketer of the Year, Communications Awards and Clinical Researcher of the Year, the Americas, are all still open for entry, while the PharmaTimes Sales Awards are set to launch in May. For more information visit www. pharmatimes.com/competitions. Also, if you’re thinking of entering the 2021 Patient Partnership Index, entry to that closes on May 14 (www. patientpartnershipindex.co.uk/enter)
Dr Mira Doig, ACM Bioanalytical Services, Technical Director
Madeline Donnelly, ADVANZ PHARMA, Commercial Director UK & Ireland
Amanda Koontz, Bionical Emas, Project Director – Early Access Programs
Laura Frost, Bionical Emas, Senior Account Manager – Clinical Trial Supply
Amrit Bagha, Bionical Emas, Director of Project Management Office - Clinical Development
Dr Kay Wardle, Coulter Partners, Managing Partner
Catherine Brassington-Richards, Havas Lynx Group, Chief Growth Officer
Rachael Mcloughlin, Havas Lynx Group, Head of Digital, H4B Manchester
Sian Carr, Ipsen, Medical Affairs Director, Oncology
Jayne Davies, Ipsen, Lead Scientist Analytical Development
Shairose Ebrahim, integrated medhealth communication (imc) group, Founder and Chief Executive Officer
Amanda Cunnington, Janssen, Patient Access and Health Affairs Director
It’s a virtual world out there. Katrina Megget asks what’s next for digital communications?
Oli Hudson, content director at Wilmington Healthcare, takes a look at the new groups of providers that are expected to play a pivotal role in integrating care
500,000 reasons why now is the time to level up IBD care and treatment across the country
Purpose proves itself: permission for pharma to explore better ways to partner with customers and regulators
Learning from the past to shape the future
Learning agility and curiosity: the way we future-proof our industry
Jackie Williams, general manager, Astellas UK & Ireland, on her achievements, COVID-19, the challenges and opportunities for pharma and the need for progress in how we value innovation
PharmaTimes talks to Dr Steve Cutler, chief executive officer at ICON plc, about the impact of the COVID pandemic and challenges of running large-scale vaccine trials
Mads Mikkelsen reminds us of the crucial role pharmacies play in the healthcare system and considers the adaptations they will have to make to thrive post-pandemic in a world that demands more from its high street
Orphan drugs in England – is disease rarity valued by decision makers?
MAGAZINE EXCLUSIVE